盐酸氨溴索联合丙酸倍氯米松雾化吸入治疗慢性阻塞性肺疾病临床观察  

Clinical observation of ambroxol hydrochloride combined with beclomethasone dipropionate aerosol inhalation in the treatment of chronic obstructive pulmonary disease

作　　者：黎志峰[1] 

机构地区：[1]陕西省宝鸡市陈仓医院,陕西宝鸡721300

出　　处：《临床医学研究与实践》2016年第26期60-61,共2页Clinical Research and Practice

摘　　要：目的探究盐酸氨溴索联合丙酸倍氯米松雾化吸入治疗慢性阻塞性肺疾病的临床疗效。方法选取我院2013年1月至2016年1月收治的130例慢性阻塞性肺疾病患者作为研究对象。随机分为对照组和观察组,每组65例患者。对照组采用盐酸氨溴索作为治疗药物,观察组在对照组的用药基础上再加入丙酸倍氯米松雾化吸入治疗。治疗结束后对比两组患者的总有效率以及不良反应(恶心、胃部灼热、消化不良)发生情况。结果观察组患者的总有效率为95.38%,明显高于对照组的81.54%,差异具有统计学意义(P<0.05);观察组患者的不良反应率为3.08%,明显低于对照组的15.38%,差异具有统计学意义(P<0.05)。结论盐酸氨溴索联合丙酸倍氯米松雾化吸入治疗慢性阻塞性肺疾病临床效果显著,可有效减少患者的不良反应发生率,值得在临床中推广及应用。Objective To explore the clinical effect of ambroxol hydroehloride combined with beelomethasone dipropionate aerosol inhalation in the treatment of chronic obstructive pulmonary disease. Methods One hundred and thirty patients with chronic obstructive pulmonary disease in our hospital from January 2013 to January 2016 were selected as study objects. The patients were randomly divided into control group and observation group, with 65 cases in each group. The control group was treated with ambroxol hydrochloride, while the observation group was treated with beelomethasone dipropionate aerosol inhalation on the basis of the control group. After the treatment, the total effective rate and adverse reactions （nausea, stomach burning, indigestion） between the two groups were compared. Results The total effective rate of the observation group was 95.38%, which was significantly higher than 81.54% of the control group, the difference was statistically significant （P〈0.05）. The adverse reaction rate of the observation group was 3.08%, which was significantly lower than 15.38% of the control group, the difference was statistically significant （P〈0.05）. Conclusion Ambroxol hydrochloride combined with beclomethasone dipropionate aerosol inhalation in the treatment of chronic obstructive pulmonary disease has a significant clinic effect, which can effectively reduce the adverse reaction rate, it is worthy promotion and application in clinic.

关 键 词：盐酸氨溴索 丙酸倍氯米松雾化吸入治疗 慢性阻塞性肺疾病 

分 类 号：R563.9[医药卫生—呼吸系统]